S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
NASDAQ:SRRK

Scholar Rock (SRRK) Stock Price, News & Analysis

$14.17
+0.15 (+1.07%)
(As of 04/11/2024 ET)
Today's Range
$13.92
$14.46
50-Day Range
$13.20
$17.76
52-Week Range
$5.56
$21.17
Volume
366,613 shs
Average Volume
1.09 million shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.17

Scholar Rock MarketRank™ Stock Analysis

Analyst Rating
Buy
3.17 Rating Score
Upside/​Downside
77.6% Upside
$25.17 Price Target
Short Interest
Bearish
16.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.83mentions of Scholar Rock in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$534,887 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.01) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.68 out of 5 stars

Medical Sector

244th out of 2,784 stocks

Biological Products, Except Diagnostic Industry

28th out of 453 stocks

SRRK stock logo

About Scholar Rock Stock (NASDAQ:SRRK)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Stock Price History

SRRK Stock News Headlines

SRRK Oct 2024 15.000 put
1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
SRRK Oct 2024 20.000 call
SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp (2QK.BE)
1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
Scholar Rock Reports Wider Loss For Full Year
SRRK Apr 2024 22.500 call
SRRK Apr 2024 10.000 put
SRRK Oct 2024 5.000 call
SRRK Oct 2024 25.000 call
SRRK Jul 2024 10.000 call
SRRK Mar 2024 7.500 put
Scholar Rock Holding Corp.
SRRK Mar 2024 15.000 call
SRRK Mar 2024 15.000 put
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/11/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRRK
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.17
High Stock Price Target
$30.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+77.6%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-165,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$33.19 million
Book Value
$3.12 per share

Miscellaneous

Free Float
57,465,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
0.90
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Edward H. Myles MBAMr. Edward H. Myles MBA (Age 52)
    CFO, COO & Treasurer
    Comp: $668.49k
  • Ms. Junlin Ho J.D. (Age 45)
    General Counsel & Corporate Secretary
    Comp: $563.73k
  • Mr. Mo Qatanani Ph.D. (Age 50)
    Chief Scientific Officer
  • Rushmie Nofsinger
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Caryn Parlavecchio (Age 52)
    Chief Human Resources Officer
  • Ms. Lisa Amaya Price
    Senior Vice President of Human Resources
  • Ms. Erin Moore (Age 49)
    Senior Vice President of Finance
  • Mr. Ryan Iarrobino
    Senior Vice President of Clinical Development & Operations
  • Dr. Jing L. Marantz M.B.A. (Age 59)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Tracey M. Sacco M.B.A. (Age 48)
    Chief Commercial Officer

SRRK Stock Analysis - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price target for 2024?

6 Wall Street analysts have issued 12-month target prices for Scholar Rock's shares. Their SRRK share price targets range from $20.00 to $30.00. On average, they expect the company's stock price to reach $25.17 in the next year. This suggests a possible upside of 77.6% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2024?

Scholar Rock's stock was trading at $18.80 at the start of the year. Since then, SRRK shares have decreased by 24.6% and is now trading at $14.17.
View the best growth stocks for 2024 here
.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its earnings results on Tuesday, March, 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.01.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

Scholar Rock (SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRRK) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners